Easton Pharmaceuticals Provides Corporate Update
2013年4月9日 - 9:30PM
ビジネスワイヤ（英語）
Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical
company that designs, develops, and markets a premium array of
topically-delivered therapeutic healthcare products announces
corporate changes to its management and business product
strategy.
As a result of various internal differences with business
strategy, Easton Pharmaceuticals execs, John K. Easton and Mr. Lee
Hendelson have mutually agreed to step down from the company. The
company has accepted the resignations of Mr. John K. Easton from
his position as CEO and chairman of the board, and the resignation
of Mr. Hendelson as CFO allowing for both individuals to undertake
other business opportunities. The Company thanks them for their
service and dedication and wishes both of them well in all future
endeavors. The company is pleased to announce Mr. John Adams, age
53, a resident of the UK and the European Union, has accepted the
position of CEO and President, while Mr. Walter Falinski assumes
the position of CFO. Mr. Adams possesses a strong background in the
field of alternative therapies and treatments, as well as holding a
strong belief that many common and serious ailments can be treated
with non evasive natural herbal remedies. His list of strong
medical contacts in the alternative therapy field and business
experience will be a valued and welcome addition to the board of
directors.
Concurrent with the resignation of Mr. Easton, the company has
canceled the acquisition of Ixora Biomedical, originally announced
in March of 2010 where it had acquired at that time all of the
remaining shares of Ixora for a 100 percent ownership interest in
the company. All Ixora shares are being returned to treasury and
canceled. The company's full ownership position in Viorra
Biomedical and all technologies associated with it including its
flagship product "Viorra" has not changed. The company has also
made the decision to change its corporate name from Easton
Pharmaceuticals to Ashley Bio Medical Inc. The name change to
Ashley BioMedical is expected to be implemented within the next 90
days.
Easton Pharmaceuticals, with the assistance of its newly added
consultants and advisors, has determined that clinical trials of
its "Viorra" product, used to naturally help treat the condition of
FSAD (female sexual arousal disorder), will be completed as
desired, but will no longer be a prerequisite prior to the
marketing and sale of the product in North America as was
previously the case. After going through changes on its formulation
for “Viorra”, the company needed to make certain that its revised
ingredients would not deviate from the GRAS designation, which is a
term used for substances that have been designated by the FDA as
safe. After undergoing an analysis on certain formulations and
ingredients of “Viorra”, a determination was made that these
concerns were unwarranted. These concerns were as a result of
changes made to its formulations over the past year. The company
believes not having to commence with an extensive, time consuming
and expensive clinical trial program will make new financing
alternatives available. As a result, the company has made the
strategic decision to immediately start assessing a marketing
program for both the North American and South American market and
to move forward with initiatives previously started in other
countries.
It is expected that the company will be announcing other changes
and additions to management and key personal in the near future to
assist with its new revised business and marketing strategy. Such
changes may include the announcement of new products and services
presently being reviewed.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company
that designs, develops, and markets a premium array of
topically-delivered therapeutic healthcare products, focused on
skin and circulatory conditions that impact a large and expanding
number of consumers including health issues related to male and
female sexual dysfunction, scar and stretch marks, cellulite and
varicose veins, the world annual market for these conditions is in
excess of $10 billion.
The company's proprietary gel formulation is an innovative and
unique transdermal delivery system. Easton Pharmaceuticals'
flagship product, VIORRA, is an over-the-counter aid for the
treatment to restore and improve vaginal elasticity and moisture,
which has a very positive effect on women's sexual desire and
arousal, helping alleviate FSAD (Female Sexual Arousal Disorder)
the world annual market for these female conditions are in excess
of $2 billion. VIORRA is a topical, daily-use product classified by
the FDA as containing Generally Recognized as Safe ingredients.
For More Information Visit http://www.eastonpharma.com and
http://www.ashleybiomedical.com
Safe Harbor
This news release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
(The "Act"). In particular, when used in the preceding of
discussion, the words "pleased," "plan," "confident that,"
"believe," "expect," or "intent to" and similar conditional
expressions are intended to identify forward-looking statements
within the meaning of the Act and are subject to the safe harbor
created by the Act. Such statements are subject to certain risks
and uncertainties and actual results could differ materially from
those expressed in any of the forward-looking statements. Such
risks and uncertainties include, but are not limited to, market
conditions, general acceptance of the company's products and
technologies, competitive factors, the ability to successfully
complete additional or adequate financing and other risks and
uncertainties as stated in the company's financial reports and
filings which all investors are urged to review.
Contact:
Easton Pharmaceuticals Inc.CEO: Dragoslav Milanovic+1(416)
619-0291+1(347) 284-0192
Investor Relations:Visit http://www.eastonpharma.com and
http://www.ashleybiomedical.comMedia relations:
media@lamindustries.comInvestor relations:
info@lamindustries.com
Easton Pharmaceuticals (CE) (USOTC:EAPH)
過去 株価チャート
から 1 2025 まで 2 2025
Easton Pharmaceuticals (CE) (USOTC:EAPH)
過去 株価チャート
から 2 2024 まで 2 2025
